Concomittant use of anticholinergic agents may decrease the effect of mosapride, as it is
excreted by activation of the cholinergic nerves.

Hence precautions should be taken when mosapride is co-administered with anticholinergic drugs  like atropine sulphate.

 

Diarrhea, dry mouth, malaise, abdominal pain, increased GOT, GPT, ALP, GTP, palpitations,dizziness, light-headedness, eosinophillia, incresed triglyceride.

 

Hypersensitivity

Special Precautions:
Continous administration of this drug is not recommended if no improvement in gastrointestinal
symptoms is observed after 2 weeks of administration.

Elderly patients with reduced physiological function of kidney and liver.

Pregnancy: Safety not established. To be used only if the benefits to the patients outweigh the risks.

Lactation: Drug to be avoided in nursing mothers.Nursing mothers should discontinue breast feeding during treatment

Safety in children- not established.

 Food does not significantly affect the bioavailability of the mosapride.

 

Indication-

Gastro-intestinal reflux disease

Dosage-

Adults- 15mg of mosapride citrate daily in 3 divided doses before or after meals.

 

MOSAPRIDE-

Refer cisapride

Drug to be discontinued if no improvement symptoms in gastrointestinal symptoms is observed.
Use in elderly patients with reduced physiological function of kidney and liver.
Pregnancy and lactation and use in children

 

Pharmacology:
Mosapride enhances upper gastrointestinal motility by stimulating the 5-hydroxytryptamine 4
receptor. It also exerts its pharmacological action by stimulation of 5-HT4 receptors in the
presynaptic nerve endings in the myenteric plexus. This facilitates acetylcholine release at the neuro-muscular junction, strengthening tone and contractions of the gut wall.

Pharmacokinatics
Mosapride is rapidly absorbed from the gastrointestinal tract, and exhibits linear
pharmacokinetics. It is bound to plasma to an extent of 99% and is metabolised in the liver,
des-4-flurobenzyl is the main metabolite formed.The Cmax is 2 to 8 times higher than that of other gastrokinetic benzamides. The elimination half life of mosapride is 14 to 2 hours.

It is excreted mainly through urine and feces. Food does not significantly affect the bioavailability of the mosapride.

 

Food does not significantly affect the bioavailability of the mosapride.

 Pregnancy:
Safety not established. To be used only if the benefits to the patients outweigh the
risks.

Lactation:
Drug to avoided in nursing mothers.Nursing mothers should discontinue brest feeding
during treatment

Children:
Safety in children- not established.